Skip to NavigationSkip to content

Top Ten most popular articles on Pharmafile.com this week

Published on 17/04/20 at 11:42am

Hydroxychloroquine dominates the news as the potential COVID-19 treatment has gone through various trials. A Chinese study showed that the drug does not speed up the recovery of coronavirus while another in Brazil was suspended after 11 patients died after taking the anti-malaria treatment. 

President Trump has continually touted it as a treatment for the virus, and there has been an increase in people abusing the drug. 

In more general industry related news, Pfizer and Eli Lilly have defeated a class action lawsuit seeking billions in damages over claims that Viagra and Cialis cause skin cancer, while Circassia Pharmaceuticals has announced its decision to break away from a partnership it forged with AstraZeneca UK back in 2017 for the development and commercialisation of two respiratory drugs for the treatment of chronic obstructive pulmonary disease (COPD).

10. AstraZeneca to pit blood cancer drug Calquence against COVID-19 with the company's fastest-ever trial launch

As the R&D race against COVID-19 continues, AstraZeneca is poised to launch a global, multicentre clinical trial to test its approved blood cancer drug Calquence (acalabrutinib) in the treatment of exaggerated immune response, also known as a cytokine storm, in patients severely ill with life-threatening COVID-19 symptoms, with the goal of ultimately reducing mortality and necessity of assisted ventilation.

9. Judge increases the amount of damages Gilead owes Bristol-Myers Squibb in CAR-T legal dispute

A judge has ruled that Gilead Sciences owe Bristol-Myers Squibb (BMS) additional funds after infringing on one of the company's patents.

8. Gilead's promising COVID-19 drug remdesivir shows benefit in 68% of hospitalised patients

Gilead has provided an update on its ongoing efforts against the novel coronavirus, revealing data from a cohort analysis of its antiviral therapy remdesivir, one of the most promising treatments for patients hospitalised by COVID-19.

7. Circassia terminates AstraZeneca partnership in exchange for £150m debt settlement

Circassia Pharmaceuticals has announced its decision to break away from a partnership it forged with AstraZeneca UK back in 2017 for the development and commercialisation of two respiratory drugs for the treatment of chronic obstructive pulmonary disease (COPD).

6. Pfizer and Eli Lilly defeat lawsuit over claims Viagra and Cialis cause cancer

Pfizer and Eli Lilly have defeated a class action lawsuit seeking billions in damages over claims that Viagra and Cialis cause skin cancer.

5. New Chinese study shows Hydroxychloroquine does not speed up COVID-19 recovery

The anti-malaria drug hydroxychloroquine does not speed up recovery from COVID-19, according to a new Chinese study.

4. US reports increase in Hydroxychloroquine misuse

The American Association of Poison Control Centers (AAPCC) has said there has been an increase in people abusing the anti-malaria drug hydroxychloroquine, after being touted by President Donald Trump as a coronavirus treatment.

3. Fatal heart complications halt Brazilian study of chloroquine in treating COVID-19

A chloroquine study investigating its effects in treating the COVID-19 coronavirus in Brazil has been postponed for safety reasons.

2. Intermittent social distancing could last until 2022, according to a new study

Social distancing that has been put in place to stem the spread of COVID-19 coronavirus could be implemented up until 2022, according to new research.

1. Sanofi and GSK set aside rivalry with "unprecedented" COVID-19 vaccine partnership

Usual rivals Sanofi and GlaxoSmithKline have said they are to put aside competition with the forging of a new “unprecedented collaboration” in the pursuit of an adjuvanted vaccine against the COVID-19 pandemic.

Mission Statement
Pharmafile.com is a leading portal for the pharmaceutical industry, providing industry professionals with pharma news, pharma events, pharma service company listings and pharma jobs,
Site content is produced by our editorial team exclusively for Pharmafile.com and our industry newspaper Pharmafocus. Service company profiles and listings are taken from our pharmaceutical industry directory, Pharmafile, and presented in a unique Find and Compare format to ensure the most relevant matches